13 new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended 13 medicines for approval at its July 2025 meeting. The committee recommended granting a marketing authorisation for Aqneursa* (levacetylleucine), for the treatment of Niemann-Pick type C, a rare, progressive, fatal genetic disorder caused by mutations encoding lysosomal proteins that are essential for the intracellular transport and metabolism of …
Read More »Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 July 2025
